Top Markets:
United States: Holding the largest share with approximately 42.6% of the global market in 2022.
China: Experiencing rapid growth and currently holding around 7.6% of the market (hospital segment only).
Japan: A mature market with a 4.5% share.
Germany: Another mature market contributing 4% to the global total.
France: Rounding out the top 5 with a 3.8% share.
Why would you choose the UK over US or even the EU for that matter? Size, hell no.
Legitmacy...laughable.
Scared they would get rejected if they tried the US first...most likely that's why they waited for this JAMA to explain the mess of the trial results and needed additional support of another RA. Oh and also they thought building the facility in the UK (for the CEO's fund at the expense of NWBO shareholders) might have helped their case. I hope to hell this never-ending scam for any real naive invested retails ends soon.
PHARMACEUTICAL MARKET VALUE (at ex–factory prices) EFPIA 2020 € million € million Austria 4,827 Belgium 6,303 Bulgaria 1,414 Croatia 1,036 Cyprus 177 Czech Rep. 3,389 Denmark 3,243 Estonia 359 Finland 2,762 France 29,552 Germany 42,962 Greece 5,381 Hungary 2,558 Iceland 183 Ireland 2,354 Italy 23,446 Latvia 275 Lithuania 866 Malta 196 Netherlands 6,185 Norway 2,597 Poland 7,239 Portugal 3,524 Romania 4,500 Russia 18,398 Serbia 871 Slovakia 1,461 Slovenia 743 Spain 17,604 Sweden 4,570 Switzerland 5,920 Turkey 6,626 U.K. 24,569
There is a reason it is usually in this order when seeking approval: US, EU, Japan. Lately, China is being thrown somewhere in that mix. You shouldn't wonder why when you look at the revenue size. Unless you drink this company's kool aid or paid by them to pump this crap.
Buyout based on UK alone, you ain't going to get much. The real BO always has and always will go through the US. You don't get that US RA, you ain't getting squat especially with that 1.7B authorized share count.
News 
Market Data 
Discover 
